These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

653 related articles for article (PubMed ID: 33520970)

  • 1. Perinatal Cells: A Promising COVID-19 Therapy?
    Papait A; Cargnoni A; Sheleg M; Silini AR; Kunis G; Ofir R; Parolini O
    Front Bioeng Biotechnol; 2020; 8():619980. PubMed ID: 33520970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients with Acute Respiratory Distress Syndrome (ARDS).
    Lanzoni G; Linetsky E; Correa D; Alvarez RA; Marttos A; Hirani K; Cayetano SM; Castro JG; Paidas MJ; Efantis Potter J; Xu X; Glassberg M; Tan J; Patel AN; Goldstein B; Kenyon NS; Baidal D; Alejandro R; Vianna R; Ruiz P; Caplan AI; Ricordi C
    CellR4 Repair Replace Regen Reprogram; 2020; 8():. PubMed ID: 34164564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use.
    Atluri S; Manchikanti L; Hirsch JA
    Pain Physician; 2020 Mar; 23(2):E71-E83. PubMed ID: 32214286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Facing the Challenges in the COVID-19 Pandemic Era: From Standard Treatments to the Umbilical Cord-Derived Mesenchymal Stromal Cells as a New Therapeutic Strategy.
    Russo E; Corrao S; Di Gaudio F; Alberti G; Caprnda M; Kubatka P; Kruzliak P; Miceli V; Conaldi PG; Borlongan CV; La Rocca G
    Cells; 2023 Jun; 12(12):. PubMed ID: 37371134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunomodulatory agents as potential therapeutic or preventive strategies for COVID-19.
    Gaziano R; Pistoia ES; Campione E; Fontana C; Marino D; Favaro M; Pica F; Di Francesco P
    Eur Rev Med Pharmacol Sci; 2021 Jun; 25(11):4174-4184. PubMed ID: 34156699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heme oxygenase-1 (HO-1) cytoprotective pathway: A potential treatment strategy against coronavirus disease 2019 (COVID-19)-induced cytokine storm syndrome.
    Rossi M; Piagnerelli M; Van Meerhaeghe A; Zouaoui Boudjeltia K
    Med Hypotheses; 2020 Nov; 144():110242. PubMed ID: 33254548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do inflammaging and coagul-aging play a role as conditions contributing to the co-occurrence of the severe hyper-inflammatory state and deadly coagulopathy during COVID-19 in older people?
    Xu K; Wei Y; Giunta S; Zhou M; Xia S
    Exp Gerontol; 2021 Aug; 151():111423. PubMed ID: 34048906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MSC Therapies for COVID-19: Importance of Patient Coagulopathy, Thromboprophylaxis, Cell Product Quality and Mode of Delivery for Treatment Safety and Efficacy.
    Moll G; Drzeniek N; Kamhieh-Milz J; Geissler S; Volk HD; Reinke P
    Front Immunol; 2020; 11():1091. PubMed ID: 32574263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mesenchymal Stem/Stromal Cells Therapy for Sepsis and Acute Respiratory Distress Syndrome.
    Byrnes D; Masterson CH; Artigas A; Laffey JG
    Semin Respir Crit Care Med; 2021 Feb; 42(1):20-39. PubMed ID: 32767301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expediting Molecular Translational Approach of Mesenchymal Stem Cells in COVID-19 Treatment.
    Balaji Easwaran V; Satarker S; V Gujaran T; John J; Veedu AP; George KT; Purayil DK; Beegum F; Mathew A; Vibhavari R; Chaudhari SS; Pai KSR
    Curr Stem Cell Res Ther; 2023; 18(5):653-675. PubMed ID: 36424799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three novel prevention, diagnostic, and treatment options for COVID-19 urgently necessitating controlled randomized trials.
    Horowitz RI; Freeman PR
    Med Hypotheses; 2020 Oct; 143():109851. PubMed ID: 32534175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mesenchymal stromal cells as potential immunomodulatory players in severe acute respiratory distress syndrome induced by SARS-CoV-2 infection.
    Mallis P; Michalopoulos E; Chatzistamatiou T; Stavropoulos-Giokas C
    World J Stem Cells; 2020 Aug; 12(8):731-751. PubMed ID: 32952855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series.
    Hashemian SR; Aliannejad R; Zarrabi M; Soleimani M; Vosough M; Hosseini SE; Hossieni H; Keshel SH; Naderpour Z; Hajizadeh-Saffar E; Shajareh E; Jamaati H; Soufi-Zomorrod M; Khavandgar N; Alemi H; Karimi A; Pak N; Rouzbahani NH; Nouri M; Sorouri M; Kashani L; Madani H; Aghdami N; Vasei M; Baharvand H
    Stem Cell Res Ther; 2021 Jan; 12(1):91. PubMed ID: 33514427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
    Stratton CW; Tang YW; Lu H
    J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mesenchymal stromal cells for acute respiratory distress syndrome (ARDS), sepsis, and COVID-19 infection: optimizing the therapeutic potential.
    Gorman E; Millar J; McAuley D; O'Kane C
    Expert Rev Respir Med; 2021 Mar; 15(3):301-324. PubMed ID: 33172313
    [No Abstract]   [Full Text] [Related]  

  • 16. A new pharmacological approach based on remdesivir aerosolized administration on SARS-CoV-2 pulmonary inflammation: A possible and rational therapeutic application.
    Contini C; Enrica Gallenga C; Neri G; Maritati M; Conti P
    Med Hypotheses; 2020 Nov; 144():109876. PubMed ID: 32562915
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensive care for seriously ill patients affected by novel coronavirus sars - CoV - 2: Experience of the Crema Hospital, Italy.
    Zuccon W; Comassi P; Adriani L; Bergamaschini G; Bertin E; Borromeo R; Corti S; De Petri F; Dolci F; Galmozzi A; Gigliotti A; Gualdoni L; Guerra C; Khosthiova A; Leati G; Lupi G; Moscato P; Perotti V; Piantelli M; Ruini A; Sportelli S; Susca M; Troiano C; Benelli G; Buscarini E; Canetta C; Merli G; Scartabellati A; Melilli B S C G; Sfogliarini R; Pellegatta G; Viganò G
    Am J Emerg Med; 2021 Jul; 45():156-161. PubMed ID: 33046317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
    Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
    Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The rationale of using mesenchymal stem cells in patients with COVID-19-related acute respiratory distress syndrome: What to expect.
    Can A; Coskun H
    Stem Cells Transl Med; 2020 Nov; 9(11):1287-1302. PubMed ID: 32779878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypothesis for the management and treatment of the COVID-19-induced acute respiratory distress syndrome and lung injury using mesenchymal stem cell-derived exosomes.
    Taghavi-Farahabadi M; Mahmoudi M; Soudi S; Hashemi SM
    Med Hypotheses; 2020 Nov; 144():109865. PubMed ID: 32562911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.